Standardization of marketed anti-obesity nutraceuticals containing amla and ginseng

摘要

The present study envisages the generation of scientific evidence to validate the claims of some marketed anti-obesity nutraceutical products. Seven products [three containing amla—Sri Sri Tattva, Jiva, Onelife amla; three containing ginseng-Lords, Dr. Bhargava, MediLexicon, and a polyherbal tablet—Onelife MultiMan] were standardized as per reported protocols. The test products complied with the dissolution profile (Q_(60) ≥ 75%). The test products evaluated for total phenolic content were found to be the highest in amla tablets (135–175 mg GAE/g) versus the ginseng tablets and the polyherbal tablet; the total flavonoid content was found to be highest in the polyherbal tablet (36.93 mg QE/g). The results of in vivo studies indicated that the test products produced a decrease in body weight, total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglyceride in obese rats. This study established the scientific evidence about the quality and efficacy of the selected marketed anti-obesity nutraceutical products.